Hikari Power Ltd grew its holdings in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 79.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 676,596 shares of the biopharmaceutical company’s stock after buying an additional 300,000 shares during the period. Hikari Power Ltd owned 2.55% of Ocera Therapeutics worth $771,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, Virtu KCG Holdings LLC raised its position in shares of Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 141,040 shares during the last quarter. Institutional investors own 20.20% of the company’s stock.
A number of brokerages have recently commented on OCRX. Zacks Investment Research cut shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. HC Wainwright cut shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 target price for the company. in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $1.69.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Want to see what other hedge funds are holding OCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocera Therapeutics, Inc. (NASDAQ:OCRX).
What are top analysts saying about Ocera Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocera Therapeutics Inc. and related companies.